Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide capsule versus budesonide-MMX add-on therapy in mesalazine-refractory ulcerative colitis
2017-004576-57Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide and budesonide MMX in autoimmune colitis (3 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Clinical and endoscopic remission rate at end of treatment or withdrawal. Started Jan 2019; status: completed.
02
Drugs
budesonidebudesonide MMX
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2017-004576-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004576-57.